158 related articles for article (PubMed ID: 22739266)
1. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
2. Sapacitabine for cancer.
Liu X; Kantarjian H; Plunkett W
Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458
[TBL] [Abstract][Full Text] [Related]
3. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Liu X; Wang Y; Benaissa S; Matsuda A; Kantarjian H; Estrov Z; Plunkett W
Blood; 2010 Sep; 116(10):1737-46. PubMed ID: 20479284
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W
Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
6. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Wang Y; Liu X; Matsuda A; Plunkett W
Cancer Res; 2008 May; 68(10):3881-9. PubMed ID: 18483273
[TBL] [Abstract][Full Text] [Related]
7. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Al Abo M; Sasanuma H; Liu X; Rajapakse VN; Huang SY; Kiselev E; Takeda S; Plunkett W; Pommier Y
Mol Cancer Ther; 2017 Nov; 16(11):2543-2551. PubMed ID: 28802254
[TBL] [Abstract][Full Text] [Related]
8. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Azuma A; Huang P; Matsuda A; Plunkett W
Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
[TBL] [Abstract][Full Text] [Related]
9. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
Liu X; Jiang Y; Nowak B; Ichikawa S; Ohtawa M; Matsuda A; Plunkett W
Cancer Chemother Pharmacol; 2020 Apr; 85(4):661-672. PubMed ID: 32072218
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W
Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915
[TBL] [Abstract][Full Text] [Related]
12. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Liu X; Matsuda A; Plunkett W
Mol Cancer Ther; 2008 Jan; 7(1):133-42. PubMed ID: 18202016
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
[TBL] [Abstract][Full Text] [Related]
16. CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death.
Liu X; Jiang Y; Takata KI; Nowak B; Liu C; Wood RD; Hittelman WN; Plunkett W
Mol Cancer Ther; 2019 Dec; 18(12):2283-2295. PubMed ID: 31501277
[TBL] [Abstract][Full Text] [Related]
17. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
[TBL] [Abstract][Full Text] [Related]
18. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of sugar-modified cytosine nucleosides.
Matsuda A; Sasaki T
Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358
[TBL] [Abstract][Full Text] [Related]
20. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]